Literature DB >> 29685063

Methylphenidate Treatment for Patients With Posterior Cortical Atrophy.

Mario F Mendez1.   

Abstract

Entities:  

Keywords:  Alzheimer-s Disease; CNS Stimulants; Cerebral Disorders; Dementia

Mesh：

Substances：

Year:  2018        PMID： 29685063      PMCID： PMC6265121          DOI： 10.1176/appi.neuropsych.17120356

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN： 0895-0172            Impact factor:   2.198


× No keyword cloud information.
  11 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.

Authors:  Paul B Rosenberg; Krista L Lanctôt; Lea T Drye; Nathan Herrmann; Roberta W Scherer; David L Bachman; Jacobo E Mintzer
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

Review 4.  Methylphenidate treatment of negative symptoms in patients with dementia.

Authors:  I Galynker; C Ieronimo; C Miner; J Rosenblum; N Vilkas; R Rosenthal
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1997       Impact factor: 2.198

5.  Attention deficit in Alzheimer's disease is not simulated by an anticholinergic/antihistaminergic drug and is distinct from deficits in healthy aging.

Authors:  B S Oken; S S Kishiyama; J A Kaye; D B Howieson
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

6.  Methylphenidate for apathy and functional status in dementia of the Alzheimer type.

Authors:  Prasad R Padala; William J Burke; Valerie K Shostrom; Subhash C Bhatia; Steven P Wengel; Jane F Potter; Frederick Petty
Journal:  Am J Geriatr Psychiatry       Date:  2010-04       Impact factor: 4.105

7.  Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy.

Authors:  D F Tang-Wai; N R Graff-Radford; B F Boeve; D W Dickson; J E Parisi; R Crook; R J Caselli; D S Knopman; R C Petersen
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

8.  Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.

Authors:  Nathan Herrmann; Lana S Rothenburg; Sandra E Black; Michelle Ryan; Barbara A Liu; Usoa E Busto; Krista L Lanctôt
Journal:  J Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.153

9.  Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease.

Authors:  Mario F Mendez; Mehdi Ghajarania; Kent M Perryman
Journal:  Dement Geriatr Cogn Disord       Date:  2002       Impact factor: 2.959

10.  Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia.

Authors:  Shibley Rahman; Trevor W Robbins; John R Hodges; Mitul A Mehta; Peter J Nestor; Luke Clark; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853
View more
  1 in total

Review 1.  Update on posterior cortical atrophy.

Authors:  Samantha K Holden; Brianne M Bettcher; Victoria S Pelak
Journal:  Curr Opin Neurol       Date:  2020-02       Impact factor: 6.283
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.